Skip to content
Back to MTRI

InMed Pharmaceuticals Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 17, 2025
Transactions
50
Purchases
50
Sales
0
Purchase value
$1.40M
Sale value
$0.00

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

ADAR1 Capital Management, LLC10% owner
Schneeberger Daniel10% owner
4
Filed Nov 9, 2026Period of report Nov 5, 20260001940272-26-000031
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseNov 5, 2026
Common SharesF1F2F3F42,640$13.0953$34.57K98,297IndirectSee Footnote
Filing footnotes · 4
  1. F1The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.9500 to $13.3000, inclusive. Each Reporting Person undertakes to provide to Mentari Therapeutics, Inc., any security holder of Mentari Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  2. F2On November 4, 2026, the Issuer effected a 1-for-10 reverse stock split of its outstanding common stock. The transaction reported herein occurred on November 5, 2026, after giving effect to the reverse stock split. On November 6, 2026, the Issuer completed its previously announced merger transaction and changed its name from InMed Pharmaceuticals Inc. to Mentari Therapeutics, Inc. and its trading symbol from INM to MTRI. Following completion of the merger and related transactions, the Reporting Persons ceased to beneficially own more than 10% of the Issuer's outstanding common stock and are no longer subject to Section 16.
  3. F3The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  4. F4For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Open on SEC EDGAR
ADAR1 Capital Management, LLC10% owner
Schneeberger Daniel10% owner
4
Filed Oct 27, 2026Period of report Oct 23, 20260001940272-26-000028
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseOct 23, 2026
Common SharesF1F24$1.32$5.28956,584IndirectSee Footnote
Filing footnotes · 2
  1. F1The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by(i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  2. F2For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent ofhis/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes ofSection 16 or otherwise.
Open on SEC EDGAR
ADAR1 Capital Management, LLC10% owner
Schneeberger Daniel10% owner
4
Filed Oct 20, 2026Period of report Oct 16, 20260001940272-26-000026
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseOct 19, 2026
Common SharesF1F21,086$1.32$1.43K956,580IndirectSee Footnote
PurchaseOct 16, 2026
Common SharesF1F21$1.32$1.32955,494IndirectSee Footnote
Filing footnotes · 2
  1. F1The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  2. F2For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Open on SEC EDGAR
ADAR1 Capital Management, LLC10% owner
Schneeberger Daniel10% owner
4
Filed Oct 15, 2026Period of report Oct 13, 20260001940272-26-000025
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseOct 15, 2026
Common SharesF1F2F3984$1.3219$1.30K955,493IndirectSee Footnote
PurchaseOct 14, 2026
Common SharesF2F38,021$1.33$10.67K954,509IndirectSee Footnote
PurchaseOct 13, 2026
Common SharesF2F3564$1.33$750.12946,488IndirectSee Footnote
Filing footnotes · 3
  1. F1The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.3200 to $1.3300, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  2. F2The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  3. F3For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Open on SEC EDGAR
ADAR1 Capital Management, LLC10% owner
Schneeberger Daniel10% owner
4
Filed Oct 8, 2026Period of report Oct 6, 20260001940272-26-000023
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseOct 8, 2026
Common SharesF2F3F42,256$1.3283$3.00K945,924IndirectSee Footnote
PurchaseOct 7, 2026
Common SharesF3F43,046$1.33$4.05K943,668IndirectSee Footnote
PurchaseOct 6, 2026
Common SharesF1F3F45,601$1.3277$7.44K940,622IndirectSee Footnote
Filing footnotes · 4
  1. F1The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.3200 to $1.3300, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  2. F2The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.3200 to $1.3300, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  3. F3The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  4. F4For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Open on SEC EDGAR
ADAR1 Capital Management, LLC10% owner
Schneeberger Daniel10% owner
4
Filed Oct 5, 2026Period of report Oct 1, 20260001940272-26-000022
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseOct 5, 2026
Common SharesF2F318,182$1.33$24.18K935,021IndirectSee Footnote
PurchaseOct 2, 2026
Common SharesF2F38,307$1.33$11.05K916,839IndirectSee Footnote
PurchaseOct 1, 2026
Common SharesF1F2F316,431$1.3298$21.85K908,532IndirectSee Footnote
Filing footnotes · 3
  1. F1The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.3200 to $1.3300, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  2. F2The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  3. F3For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Open on SEC EDGAR
ADAR1 Capital Management, LLC10% owner
Schneeberger Daniel10% owner
4
Filed Sep 16, 2026Period of report Sep 14, 20260001940272-26-000021
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseSep 16, 2026
Common SharesF3F4F58,340$1.289$10.75K892,101IndirectSee Footnote
PurchaseSep 15, 2026
Common SharesF2F4F554,256$1.2984$70.45K883,761IndirectSee Footnote
PurchaseSep 14, 2026
Common SharesF1F4F528,505$1.2938$36.88K829,505IndirectSee Footnote
Filing footnotes · 5
  1. F1The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.2900 to $1.3100, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  2. F2The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.2800 to $1.3000, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  3. F3The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.2600 to $1.3000, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  4. F4The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  5. F5For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Open on SEC EDGAR
Vivo Opportunity Cayman Fund, L.P.10% owner
Vivo Opportunity Cayman, LLC10% owner
Vivo Opportunity Fund Holdings, L.P.10% owner
Vivo Opportunity, LLC10% owner
4
Filed Jul 16, 2026Period of report Jul 14, 20260001213900-26-078891
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseJul 16, 2026
Common SharesF119$1.55$29.45743,057IndirectBy Vivo Opportunity Fund Holdings, L.P.
PurchaseJul 16, 2026
Common SharesF22$1.55$3.1075,019IndirectBy Vivo Opportunity Cayman Fund, L.P.
PurchaseJul 15, 2026
Common SharesF113,761$1.55$21.33K743,038IndirectBy Vivo Opportunity Fund Holdings, L.P.
PurchaseJul 15, 2026
Common SharesF21,389$1.55$2.15K75,017IndirectBy Vivo Opportunity Cayman Fund, L.P.
PurchaseJul 14, 2026
Common SharesF14,882$1.55$7.57K729,277IndirectBy Vivo Opportunity Fund Holdings, L.P.
PurchaseJul 14, 2026
Common SharesF2493$1.55$764.1573,628IndirectBy Vivo Opportunity Cayman Fund, L.P.
Filing footnotes · 2
  1. F1Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
  2. F2Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
Open on SEC EDGAR
ADAR1 Capital Management, LLC10% owner
Schneeberger Daniel10% owner
4
Filed Jul 17, 2026Period of report Jul 15, 20260001940272-26-000010
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseJul 15, 2026
Common SharesF1F21,000$1.555$1.56K801,000IndirectSee Footnote
Filing footnotes · 2
  1. F1The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  2. F2For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Open on SEC EDGAR
Vivo Opportunity Cayman Fund, L.P.10% owner
Vivo Opportunity Cayman, LLC10% owner
Vivo Opportunity Fund Holdings, L.P.10% owner
Vivo Opportunity, LLC10% owner
4
Filed Jul 2, 2026Period of report Jun 30, 20260001213900-26-075144
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseJul 2, 2026
Common SharesF5F11,460$1.55$2.26K724,395IndirectBy Vivo Opportunity Fund Holdings, L.P.
PurchaseJul 2, 2026
Common SharesF5F2147$1.55$227.8573,135IndirectBy Vivo Opportunity Cayman Fund, L.P.
PurchaseJul 1, 2026
Common SharesF4F13,946$1.55$6.12K722,935IndirectBy Vivo Opportunity Fund Holdings, L.P.
PurchaseJul 1, 2026
Common SharesF4F2398$1.55$616.9072,988IndirectBy Vivo Opportunity Cayman Fund, L.P.
PurchaseJun 30, 2026
Common SharesF3F1545$1.54$839.30718,989IndirectBy Vivo Opportunity Fund Holdings, L.P.
PurchaseJun 30, 2026
Common SharesF3F255$1.54$84.7072,590IndirectBy Vivo Opportunity Cayman Fund, L.P.
Filing footnotes · 5
  1. F1Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
  2. F2Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
  3. F3The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.52 to $1.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4.
  4. F4The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.51 to $1.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4.
  5. F5The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.55 to $1.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (5) to this Form 4.
Open on SEC EDGAR
Vivo Opportunity Cayman Fund, L.P.10% owner
Vivo Opportunity Cayman, LLC10% owner
Vivo Opportunity Fund Holdings, L.P.10% owner
Vivo Opportunity, LLC10% owner
4
Filed Jun 10, 2026Period of report May 20, 20260001213900-26-067505
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseJun 8, 2026
Common SharesF11F129,518$1.52$44.87K718,444IndirectBy Vivo Opportunity Fund Holdings, L.P.
PurchaseJun 8, 2026
Common SharesF11F22,982$1.52$4.53K72,535IndirectBy Vivo Opportunity Cayman Fund, L.P.
PurchaseJun 5, 2026
Common SharesF10F149,966$1.57$78.45K688,926IndirectBy Vivo Opportunity Fund Holdings, L.P.
PurchaseJun 5, 2026
Common SharesF10F25,045$1.57$7.92K69,553IndirectBy Vivo Opportunity Cayman Fund, L.P.
PurchaseJun 4, 2026
Common SharesF9F16,125$1.57$9.62K638,960IndirectBy Vivo Opportunity Fund Holdings, L.P.
PurchaseJun 4, 2026
Common SharesF9F2618$1.57$970.2664,508IndirectBy Vivo Opportunity Cayman Fund, L.P.
PurchaseJun 3, 2026
Common SharesF8F17,069$1.55$10.96K632,835IndirectBy Vivo Opportunity Fund Holdings, L.P.
PurchaseJun 3, 2026
Common SharesF8F2714$1.55$1.11K63,890IndirectBy Vivo Opportunity Cayman Fund, L.P.
PurchaseJun 2, 2026
Common SharesF7F120,753$1.52$31.54K625,766IndirectBy Vivo Opportunity Fund Holdings, L.P.
PurchaseJun 2, 2026
Common SharesF7F22,095$1.52$3.18K63,176IndirectBy Vivo Opportunity Cayman Fund, L.P.
PurchaseJun 1, 2026
Common SharesF6F114,838$1.55$23.00K605,013IndirectBy Vivo Opportunity Fund Holdings, L.P.
PurchaseJun 1, 2026
Common SharesF6F21,498$1.55$2.32K61,081IndirectBy Vivo Opportunity Cayman Fund, L.P.
PurchaseMay 29, 2026
Common SharesF5F116,164$1.57$25.38K590,175IndirectBy Vivo Opportunity Fund Holdings, L.P.
PurchaseMay 29, 2026
Common SharesF5F21,632$1.57$2.56K59,583IndirectBy Vivo Opportunity Cayman Fund, L.P.
PurchaseMay 21, 2026
Common SharesF4F130,882$1.69$52.19K574,011IndirectBy Vivo Opportunity Fund Holdings, L.P.
PurchaseMay 21, 2026
Common SharesF4F23,118$1.69$5.27K57,951IndirectBy Vivo Opportunity Cayman Fund, L.P.
PurchaseMay 20, 2026
Common SharesF3F151,056$1.56$79.65K543,129IndirectBy Vivo Opportunity Fund Holdings, L.P.
PurchaseMay 20, 2026
Common SharesF3F25,154$1.56$8.04K54,833IndirectBy Vivo Opportunity Cayman Fund, L.P.
Filing footnotes · 11
  1. F1Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
  2. F10The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.53 to $1.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (10) to this Form 4.
  3. F11The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.48 to $1.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (11) to this Form 4.
  4. F2Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
  5. F3The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.42 to $1.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4.
  6. F4The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.53 to $1.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4.
  7. F5The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.55 to $1.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (5) to this Form 4.
  8. F6The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.49 to $1.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (6) to this Form 4.
  9. F7The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.49 to $1.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (7) to this Form 4.
  10. F8The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.50 to $1.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (8) to this Form 4.
  11. F9The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.55 to $1.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (9) to this Form 4.
Open on SEC EDGAR
ADAR1 Capital Management, LLC10% owner
Schneeberger Daniel10% owner
4
Filed May 21, 2026Period of report May 19, 20260001940272-26-000008
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseMay 19, 2026
Common SharesF1F4F568,551$1.5998$109.67K400,000IndirectSee Footnote
PurchaseMay 19, 2026
Common SharesF2F4F5200,000$1.5604$312.08K600,000IndirectSee Footnote
PurchaseMay 19, 2026
Common SharesF3F4F5200,000$1.499$299.80K800,000IndirectSee Footnote
Filing footnotes · 5
  1. F1The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.5700 to $1.6000, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  2. F2The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.5100 to $1.6000, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  3. F3The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.4350 to $1.5700, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  4. F4The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  5. F5For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.